EU Approves Expanded Age Use for GSK's RSV Vaccine Arexvy
Ticker: GLAXF · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, pharmaceuticals, vaccine
TL;DR
EU greenlights GSK's Arexvy for 50-59 year olds at risk for RSV.
AI Summary
On August 29, 2024, GSK plc announced that the European Commission has approved an expanded age indication for its respiratory syncytial virus (RSV) vaccine, Arexvy. This approval allows Arexvy to be used for individuals aged 50-59 who are at increased risk of RSV.
Why It Matters
This expanded approval broadens the market for GSK's Arexvy, potentially increasing sales and providing protection to a larger at-risk population.
Risk Assessment
Risk Level: low — This filing is a routine notification of regulatory approval and does not involve significant financial transactions or operational changes that would typically increase risk.
Key Players & Entities
- GSK plc (company) — Registrant and developer of Arexvy
- Arexvy (product) — RSV vaccine
- European Commission (company) — Regulatory body granting approval
- August 29, 2024 (date) — Date of announcement and approval
FAQ
What is the specific indication for which Arexvy received expanded approval in the EU?
The European Commission approved the expanded age indication for Arexvy for individuals aged 50-59 who are at increased risk of RSV.
When was this approval announced by GSK plc?
The approval was announced on August 29, 2024.
What is the primary function of Arexvy?
Arexvy is a vaccine for respiratory syncytial virus (RSV).
Which regulatory body granted the expanded approval for Arexvy?
The European Commission granted the expanded approval.
What was GSK plc formerly known as?
GSK plc was formerly known as GlaxoSmithKline plc, with a name change effective January 5, 2001.
Filing Stats: 1,510 words · 6 min read · ~5 pages · Grade level 11.4 · Accepted 2024-08-29 06:58:12
Filing Documents
- a0522c.htm (6-K) — 50KB
- 0001654954-24-011221.txt ( ) — 51KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: August 29,2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc